Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
Niranjan Awasthi(University of Notre Dame), Roderich E. Schwarz(Roswell Park Comprehensive Cancer Center)
Cited by 35
Related Papers
Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling
|Laboratory Investigation|2008|65
Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
|PLoS ONE|2013|33
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
|Journal of Experimental & Clinical Cancer Research|2013|30
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
|BMC Cancer|2011|26
Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
|Journal of Cellular and Molecular Medicine|2021|24